Eagle Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€220.98M - Cost of goods sold
€66.65M - Gross profit
€154.33M - SG&A expenses
€88.57M - R&D expenses
€30.59M - EBITDA
€50.09M - D&A
€18.58M - EBIT
€20.29M - Interest expenses
€5.61M - EBT
€28.13M - Tax expenses
€14.78M - Net income
€13.36M
Cash flow statement
- Net deferred tax
-€6.73M - Non-cash items
€2.99M - Changes in working capital
-€49.45M - Operating cash flow
-€7.99M - Capex
€63.49K - Other investing cash flow
-€10.73M - Net investing cash flow
-€20.43M - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€20.82M - Other financing cash flow
-€2.05M - Net financing cash flow
€10.23M - Foreign exchange effects
€0.00 - Net change in cash
-€18.20M - Cash at end of period
€13.17M - Free cash flow
-€7.93M
Balance sheet
- Cash and cash equivalents
€13.17M - Cash and short-term investments
€13.17M - Total receivables
€99.77M - Inventory
€36.45M - Other current assets
€11.27M - Total current assets
€160.66M - Property, plant & equipment
€869.15K - Goodwill
€38.64M - Intangible assets
€92.15M - Long-term investments
€15.73M - Other non-current assets
€12.93M - Total non-current assets
€186.68M - Total assets
€347.34M - Accounts payable
€13.59M - Short-term debt
€8.34M - Other current liabilities
€51.40M - Total current liabilities
€74.33M - Long-term debt
€53.11M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€3.65M - Total non-current liabilities
€56.76M - Total liabilities
€131.09M - Common stock
€15.44K - Retained earnings
€105.03M - Other equity
-€954.10K - Total equity
€216.25M - Total liabilities and shareholders' equity
€347.34M
Company information
- Market capitalization
€32.05M - Employees
134 - Enterprise Value
€42.27M
Company ratios
- Gross margin
-
69.8% Much worse than peer group: 780.4% - EBITDA margin
-
22.7% Much worse than peer group: 1,622,229.8% - EBIT margin
-
9.2% Much worse than peer group: 1,527,760.7% - EBT margin
-
12.7% Much worse than peer group: 1,622,725.9% - Net margin
-
6.0% Much worse than peer group: 1,471,182.0% - ROE
-
6.2% Much better than peer group: -24.9% - ROA
-
3.8% Better than peer group: -16.0% - Asset turnover
-
63.6% Better than peer group: 53.7% - FCF margin
-
-3.6% Much worse than peer group: 1,141,145.3% - FCF yield
-25.1% - Efficiency ratio
77.3% - Net sales per employee
-
€1.65M - Net income per employee
-
€99.67K